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Reprogramming of metabolic pathways contributes
to human disease, especially cancer, but the regula-
tors of this process are unknown. Here, we have
generated a mouse knockout for the mitochondrial
chaperone TRAP-1, a regulator of bioenergetics in
tumors. TRAP-1/ mice are viable and showed
reduced incidence of age-associated pathologies,
including obesity, inflammatory tissue degenera-
tion, dysplasia, and spontaneous tumor formation.
This was accompanied by global upregulation of
oxidative phosphorylation and glycolysis transcrip-
tomes, causing deregulated mitochondrial respira-
tion, oxidative stress, impaired cell proliferation,
and a switch to glycolytic metabolism in vivo. These
data identify TRAP-1 as a central regulator of mito-
chondrial bioenergetics, and this pathway could
contribute to metabolic rewiring in tumors.INTRODUCTION
The control of protein folding in subcellular organelles,
including mitochondria (Kang et al., 2007), maintains cellular
homeostasis (Ellis, 2007) by buffering proteotoxic stress and
ensuring flexible adaptation to environmental cues (Balch
et al., 2008). In mitochondria, a network of chaperones of the
heat shock protein-90 (Hsp90) gene family (Kang et al.,
2007), including Hsp90 (Taipale et al., 2010) and its related ho-
molog TNFR-associated protein-1 (TRAP-1) (Lavery et al.,
2014), protects against oxidative stress and permeability tran-
sition-induced apoptosis (Altieri et al., 2012). This pathway is
exploited in cancer, where mitochondrial Hsp90s are dramati-
cally upregulated, compared to normal tissues (Kang et al.,
2007).Recent evidence suggests that mitochondrial Hsp90s may
play a more global role in organelle homeostasis. Mechanisti-
cally, this involves protein-folding quality control of a discrete
mitochondrial Hsp90 proteome, overseeing gene expression,
protein translation, redox balance, and a host of metabolic path-
ways (Chae et al., 2013). In this context, mitochondrial Hsp90s,
including TRAP-1, preserve the association of the first enzyme
of glycolysis, hexokinase II (HK-II) (Ward and Thompson, 2012)
to the organelle outer membrane (Chae et al., 2012), and ensure
the folding/stability of the oxidative phosphorylation complex II
subunit (Wallace, 2012), succinate dehydrogenase, SDHB
(Chae et al., 2013). These functions are important for cellular
homeostasis, because targeting TRAP-1 by pharmacologic or
genetic approaches irreversibly compromises mitochondrial
integrity, impairs both glycolysis (Chae et al., 2012) and oxidative
phosphorylation (Chae et al., 2013), and may provide a novel
anticancer strategy in humans (Altieri et al., 2012).
However, how TRAP-1 regulation of mitochondrial homeosta-
sis fits with general mechanisms of tumor metabolic reprogram-
ming (Ward and Thompson, 2012) has not been clearly delin-
eated. Known as the ‘‘Warburg effect’’ (Ward and Thompson,
2012), most tumors rewire their energy sources toward aerobic
glycolysis and at the expense of mitochondrial respiration (Wal-
lace, 2012). Together with the identification of mutations in
oxidative phosphorylation subunits that produce ‘‘oncometabo-
lites’’ (Lu et al., 2012; Turcan et al., 2012) or stabilize oncogenes,
such as HIF1a (Selak et al., 2005), this has suggested that mito-
chondrial bioenergetics has limited (if any) role in cancer (Ward
and Thompson, 2012) and may actually function as a ‘‘tumor
suppressor’’ (Frezza et al., 2011). In this context, the role of mito-
chondrial Hsp90s in bioenergetics has become controversial, as
conflicting reports in the literature have claimed that TRAP-1
actually inhibits SDHB activity in tumor cells, promoting the
accumulation of the oncometabolite, succinate (Sciacovelli
et al., 2013), or, conversely, acts as a potential ‘‘tumor suppres-
sor’’ through stimulation of glucose metabolism (Yoshida et al.,
2013).Cell Reports 8, 671–677, August 7, 2014 ª2014 The Authors 671
Figure 1. Characterization of TRAP-1/
Mice
(A) Map of the gene trapping construct and posi-
tion of the b-galactosidase cassette inserted in the
mouse TRAP-1 locus.
(B) PCR genotyping of TRAP-1 wild-type
(WT, +/+), heterozygous (+/), and homozygous
(/) mice. The position of WT and LacZ alleles is
indicated.
(C) The indicated tissue extracts from WT or
TRAP-1 knockout (KO) mice were analyzed by
western blotting.
(D) WT or TRAP-1 KO mice were analyzed for
changes in body weight at the indicated ages (mo,
months). Data are represented as box plots.
Ages <3 months (top), WT, n = 16; KO, n = 15;
ages >12months (bottom), WT, n = 16; KO, n = 26.
*p = 0.033–0.022.
(E) Heatmap of changes in protein expression and/
or phosphorylation in liver extracts isolated from
WT or TRAP-1 KO mice (A–C, replicates; D,
average), as determined by Reverse Phase Protein
Array (RPPA). Blue, downregulated; red, upregu-
lated. Only statistically significant changes (p <
0.05) are shown.
(F) Liver extracts from WT or TRAP-1 KO mice
were analyzed by western blotting. M, male; F,
female.To clarify mechanisms of metabolic rewiring in mitochondria,
and conclusively elucidate the function of mitochondrial
Hsp90s in bioenergetics, we have now generated TRAP-1
knockout mice.
RESULTS
Generation of TRAP-1 Knockout Mice
Using gene-trap technology, we obtained mouse ES cells in
which a b-galactosidase gene disrupts the TRAP-1 locus on
chromosome 16, downstream of exon 1 (Figure 1A). Transfer
of TRAP-1-targeted zygotes into C57Bl/6 pseudopregnant
recipient mice generated TRAP-1 knockout animals. In genotyp-
ing experiments, PCR products of 565 nt, or, conversely, 1,148
nt identified the wild-type (WT) TRAP-1 allele or the b-galactosi-
dase (LacZ)-containing allele, respectively (Figure 1B). TRAP-1
knockout (TRAP-1/) mice were born viable, fertile, and at
expected Mendelian rates for both genders. Analysis of tissues
from TRAP-1/ mice, including liver, kidney, uterus, spleen,
brain, heart, and testis confirmed the absence of TRAP-1 pro-
tein, compared toWT littermates, bywestern blotting (Figure 1C).
Histologic analysis of 15-month-old TRAP-1/ mice revealed
significantly reduced incidence of multiple age-associated pa-
thologies. Compared to age-matched WT littermates, these
included lower body weight (Figure 1D) and organ (liver, spleen)672 Cell Reports 8, 671–677, August 7, 2014 ª2014 The Authorshyperplasia (Figure S1A), decreased
chronic inflammatory infiltrates in lung,
stomach, pancreas, and small intestine
(Figure S1B), lower hepatic lipidosis (Fig-
ure S1C), and reduced pancreatic fibrotic
degeneration (Figure S1B). Two out of
three WT mice examined at this age harbored spontaneous tu-
mors or dysplastic lesions, including bronchoalveolar adenoma,
dental dysplasia, and histiocytic sarcoma (Figures S1D–S1H). In
contrast, no tumors or dysplasia were detected in age-matched
TRAP-1/ mice. In terms of blood chemistry parameters, a
complete blood count was unremarkable between the various
animal groups (Figure S1I), whereas TRAP-1/ mice showed
decreased blood levels of glucose (see below) and creatinine,
compared to WT animals (Figure S1J).
We next profiled signaling pathways in WT or TRAP-1/mice
by Reverse Phase Protein Array (RPPA). Consistent with a role of
mitochondria in ‘‘retrograde’’ signaling and nuclear gene expres-
sion (Butow and Avadhani, 2004), TRAP-1 deletion was associ-
ated with general reduction in growth factor receptor activity
(MIG6, Her3, EGFR, MEK2, and PI3K), attenuated TGFb re-
sponses (Smad1 and Smad3), modulation of cell-cell and cell-
matrix communication (N-cadherin, E-cadherin, b-catenin,
transglutaminase, fibronectin), and stimulation of cell-cycle tran-
sitions (p21, Rb1, E2F1, cyclin E1, PCNA) (Figure 1E). TRAP-1
deficiency also profoundly affected bioenergetics pathways.
Consistent with recent observations (Chae et al., 2013), TRAP-
1 loss resulted in significantly reduced levels of mitochondrial
complex II subunit, SDHB (Figure 1E). This was associated
with reduced expression of fatty acid synthase and mitochon-
drial complex IV subunit, Cox-IV, upregulation of complex V
Figure 2. TRAP-1 Regulation of Mitochon-
drial Oxidative Phosphorylation
(A) Mitochondria isolated from WT or KO hepato-
cytes were analyzed for complex I activity. The
quantification of the slope (s) per each reaction is
indicated. Representative experiment.
(B) Quantification of complex-I-specific activity in
WT or KOmitochondria. Mean ± SD (n = 3). ns, not
significant (p = 0.67).
(C, F, and H) Representative experiments of mito-
chondrial complex II (C), complex II+III (F), or com-
plex IV (H) activity inmitochondria isolated fromWT
or KO hepatocytes. The quantification of the slope
(s) per each reaction is indicated.Mean±SD (n = 3).
(D, G, and I) Quantification of mitochondrial
complex-II (D), complex-II–III (G), or complex-IV (I)
-specific activity in WT or KO hepatocytes. Data
per each mitochondrial complex activity were
normalized against citrate synthase activity.
Mean ± SD (n = 3). ns, not significant (p = 0.66).
*p = 0.027–0.033.
(E) Representative experiment of mitochondrial
complex II activity in the presence or absence of
mitochondrial Hsp90 inhibitor, Gamitrinib (Gam)
The slope of individual curves is as follows,
WT-Gam, s = 0.0005; WT+Gam, s = 0.0004;
KO-Gam, s = 0.0005; KO+Gam, s = 0.0005.
(J) WT or TRAP-1 KO hepatocytes (left) or
mouse embryonic fibroblasts (MEFs) (right) were
analyzed for oxygen consumption. Data were
normalized for cell number by direct counting
and cell viability by a fluorescence reporter. Mean
± SD (n = 3) of replicates of a representative
experiment. *p = 0.015–0.036.subunit, ATP5H, and higher levels of the glycolytic enzyme,
G6PD (Figure 1E). Decreased Cox-IV expression in TRAP-1/
mice versus WT samples was confirmed by western blotting
(Figure 1F). In addition, liver extracts of TRAP-1/mice showed
increased recruitment of cytoprotective chaperones Hsp90
(Kang et al., 2007) and Hsp27 to mitochondria, whereas
levels of Hsp70, Hsp60, or VDAC were unchanged in WT or
TRAP-1/ mice (Figure 1F).
Requirement of TRAP-1 for Mitochondrial Oxidative
Phosphorylation
To examine a role of TRAP-1 in cellular respiration (Chae et al.,
2013), we next used purified mitochondria from primary hepa-
tocytes (Figure S2A) and nontransformed mouse embryonic
fibroblasts (MEFs) (Figure S2B). In these experiments, citrate
synthase-normalized (Figure S2C) mitochondrial complex I
activity was not significantly different between WT and TRAP-
1/ mice (Figure 2A), as assessed in three independent mito-
chondrial preparations (Figure 2B). Complex II activity, which
was proposed to be inhibited by TRAP-1 (Sciacovelli et al.,
2013), was instead unchanged between the two animal groups
(Figures 2C and 2D). In addition, treatment with Gamitrinib, a
small molecule antagonist that target TRAP-1/Hsp90 selectively
in mitochondria (Chae et al., 2012), inhibited complex II activity in
WT mitochondria but had no effect on TRAP-1/ samples (Fig-
ure 2E), consistent with the absence of its target, TRAP-1, in
these cells. Conversely, mitochondria isolated from TRAP-1/hepatocytes showed significantly increased activity of complex
III (Figures 2F and 2G), as well as complex IV (Figures 2H and
2I), compared to WT samples. Consistent with these data, mito-
chondrial respiration was deregulated in TRAP-1/ mice and
resulted in aberrantly increased oxygen consumption levels,
compared to WT cultures (Figure 2J).
The mechanistic underpinning of deregulated cellular respira-
tion in TRAP-1 knockout mice was further investigated. Accord-
ingly, deletion of TRAP-1 resulted in a global compensatory
upregulation of an oxidative phosphorylation ‘‘transcriptome,’’
with increased expression of virtually every subunit of mitochon-
drial respiration complexes (Figures S2D–S2H). Compared to
WT littermates, this included an average fold increase of 1.31 ±
0.03 (n = 33) for complex I subunits, 1.42 ± 0.081 (n = 4) for
complex II, 1.36 ± 0.025 (n = 7) for complex III, and 1.3 ± 0.06
(n = 24) for complex V (Figures S2D–S2F and S2H). Two subunits
in complex IV, Cox4i2 and Cox6b2, increased by approximately
4- and 20-fold, respectively, in TRAP-1/ mice, compared to
WT littermates, by array analysis (Figure S2G), as well as quan-
titative RT-PCR (Figure S2I), resulting in a 2.86 ± 1.34 (n = 15)
average fold increase for all complex IV subunits. In contrast,
overall mitochondrial DNA content was unchanged in WT or
TRAP-1/ mice (Figure S2J).
Glycolytic Reprogramming in TRAP-1 Knockout Mice
In addition to mitochondrial oxidative phosphorylation, TRAP-1
has been linked to the regulation of glycolysis (Chae et al.,Cell Reports 8, 671–677, August 7, 2014 ª2014 The Authors 673
Figure 3. Glycolytic Reprogramming
Induced by TRAP-1 Deficiency
(A and B) Mitochondria isolated from WT or
TRAP-1 KO hepatocytes (top) or MEFs (bottom)
were analyzed for glucose consumption (A) or
lactate generation (B). Data were normalized for
cell number by direct cell counting and cell viability
by a fluorescence reporter. Mean ± SD (n = 3) of
replicates. ***p = 0.0001–0.0009; **p = 0.0057.
(C) Whole-body PET/CT coronal (top) or axial
(bottom) images of a WT (left) and TRAP-1 KO
(right) mouse obtained 1 hr post 18F-FDG injection.
Three times greater uptake of radioactivity in the
liver of the TRAP-1 KO mouse represents
increased glucose consumption. SUV, standard-
ized uptake values.
(D) Quantification of hepatic standardized uptake
values (SUVs) of 18F-FDG as determined by PET/
CT analysis in WT or TRAP-1 KO mice. Each point
corresponds to an individual mouse. *p = 0.03 by
Kolmogorov-Smirnov two-sample test.
(E) Mitochondria isolated from WT or TRAP-1 KO
hepatocytes (left) or MEFs (right) were analyzed for
ATP production. Mean ± SD (n = 3) of replicates.
**p = 0.0025.
(F and G) WT or TRAP-1 KO MEFs were trans-
fected with vector or Myc-TRAP-1 cDNA and
analyzed by western blotting (F) or glucose con-
sumption (G). Mean ± SD (n = 3) of replicates of a
representative experiment. ***p < 0.0001.2012; Yoshida et al., 2013), and this function was next investi-
gated. Similar to the changes in mitochondrial respiration (Fig-
ures S2C–S2G), but in contrast with a recent report (Yoshida
et al., 2013), deletion of TRAP-1 resulted in uniformly upregu-
lated expression of a glycolysis ‘‘transcriptome’’ (Figure S3).
This involved an average fold increase of 2.36 ± 0.33 (n =
22) for regulators of glycolysis (Figure S3A), 2.28 ± 0.4 (n =
6) for glucose metabolism (Figure S3B), 1.38 ± 0.11 (n = 29)
for the TCA cycle (Figure S3C), and 1.61 ± 0.27 (n = 4) for
glycogen synthesis (Figure S3D). There was also an average
fold increase of 1.78 ± 0.26 (n = 6) for molecules involved in
glycogen degradation (Figure S3E), 1.52 ± 0.044 (n = 7) for
gluconeogenesis (Figure S3F), and 1.42 ± 0.19 (n = 10) for
the pentose phosphate pathway (Figure S3G). Expression of
sodium-independent glucose transporters Slc2a2 (Glut2)
and Slc2a10 (Glut10) was also increased in TRAP-1/ hepato-
cytes, whereas the levels of other glucose transporters, Slc2a4
(Glut4), Slc2a8 (Glut8), and Slc2a9 (Glut9) was unchanged,
compared to WT cultures (Figures S4A and S4B). Consis-
tent with these changes, TRAP-1/ hepatocytes or MEFs
dramatically switched their metabolism to aerobic glycolysis
compared to WT controls, as reflected by higher glucose674 Cell Reports 8, 671–677, August 7, 2014 ª2014 The Authorsconsumption (Figure 3A), and increased
lactate production (Figure 3B).
To quantify glycolytic reprogramming,
in vivo, we next carried out 18F-FDG
whole-body positron emission tomogra-
phy (PET)/computed tomography (CT)
scans of WT or TRAP-1/mice. In these
experiments, TRAP-1/mice exhibited a 2- to 3-fold increase in
standardized uptake values (SUVs) of the radioactive tracer in
the liver, compared to WT littermates, as determined 1 hr post-
injection of 18F-FDG (Figures 3C and 3D). Consistent with these
data, and together with the increased mitochondrial respiration
associated with TRAP-1 deletion (Figure 2), hepatocytes or
MEFs isolated from TRAP-1/mice exhibited greater ATP pro-
duction than WT cultures (Figure 3E). Despite their switch to
glycolytic metabolism, TRAP-1-deleted cells were as sensitive
asWT cultures to apoptosis induced by glucose deprivation (Fig-
ure S4C), or treatment with the nonmetabolizable glucose
analog, 2-deoxyglucose (2-DG) (Figure S4D), potentially reflect-
ing the higher levels of cytoprotective chaperones Hsp90 and
Hsp27 in mitochondria (Figure 1F). To independently validate a
role of TRAP-1 in glycolytic reprogramming, we next
reconstituted WT or TRAP-1/ MEFs with control vector or a
Myc-TRAP-1 cDNA (Figure 3F). Transient re-expression of
TRAP-1 was sufficient to normalize the glycolytic phenotype
in these cells, lowering glucose consumption to the levels of
WT MEFs (Figure 3G). In contrast, transfection of a TRAP-1
cDNA in WT cultures had no effect on glucose consumption
(Figure 3G).
Figure 4. TRAP-1 Deficiency Induces Low-
Level Oxidative Damage and Cell-Cycle
Defects
(A) WT or TRAP-1 KO MEFs were analyzed for
ROS production by flow cytometry. Data are
expressed as mean geometric fluorescence.
Mean ± SD (n = 5) of replicates of a representative
experiment. ***p = 0.0001.
(B and C) WT or TRAP-1 KO MEFs were analyzed
for gH2AX reactivity by fluorescence microscopy
(B) and quantified as normalized mean fluores-
cence (C). Mean ± SD (n = 79 for WT and n = 71 for
KO cells). Nuclei were stained with DAPI. None,
untreated; Etop, etoposide. Magnification, 360.
***p = 0.0003.
(D) WT or TRAP-1 KOMEFs were analyzed for cell
proliferation at the indicated time intervals by
direct cell counting. Mean ± SD (n = 3) of repli-
cates. Representative experiment.
(E) WT or TRAP-1 KO MEFs were stained with
propidium iodide and analyzed for DNA content by
flow cytometry. The percentage of cells in the
various cell-cycle transitions is indicated.
(F) WT or TRAP-1 KO MEFs were analyzed by
western blotting.We next asked whether targeting TRAP-1 in tumor cells, which
have typically a different bioenergetics profile from normal
tissues (Ward and Thompson, 2012), also resulted in metabolic
reprogramming. Transfection of prostate adenocarcinoma PC3
cells with four independent TRAP-1-directed siRNAs efficiently
silenced TRAP-1 expression (Figure S4E), consistent with previ-
ous observations (Chae et al., 2012). Within 6 days of TRAP-1
silencing, these cells already exhibited compensatory increased
recruitment of Hsp90 to mitochondria, compared to control
transfectants (Figure S4E), thus similar to TRAP-1/ mice (Fig-
ure 1F). Second, we established clones of cervical carcinoma
HeLa cells selected for stable small hairpin RNA (shRNA) knock-
down of TRAP-1 (Figure S4F). Analysis of these cells also re-
vealed compensatory metabolic reprogramming, with increased
oxygen consumption (Figure S4G), and higher ATP production
(Figure S4H), compared to shRNA controls, in a response that
correlated with the degree of TRAP-1 depletion (Figure S4F).
TRAP-1 Regulation of Oxidative Damage
Deregulated mitochondrial function as observed in TRAP-1/
cells may result in oxidative stress, and this possibility was
next investigated. In these experiments, TRAP-1/ MEFs ex-
hibited a modest, but significant increased production of
reactive oxygen species (ROS), compared to WT cultures (Fig-
ures 4A and S4I). TRAP-1 deletion also resulted in consistently
higher ROS production in response to increasing oxidative
stress (H2O2), compared to WT cultures (Figure S4J). Consis-
tent with increased sensitivity to oxidative damage, TRAP-1
KO cells stained positive for markers of a DNA damage
response, as reflected by increased reactivity for phosphory-
lated H2AX (gH2AX) (Figures 4B and 4C). Under these condi-
tions, TRAP-1/MEFs exhibited profound defects in cell prolif-
eration compared to WT cultures (Figure 4D), coinciding with
cell-cycle arrest at G2/M (Figure 4E), and accumulation ofmitotic
cyclin B1 (Figure 4F). In contrast, the expression of cyclin A orCdk2 was unchanged, and p21 levels were reduced in TRAP-
1/MEFs (Figure 4G), consistent with the data of RPPA profiling
(Figure 1D).
DISCUSSION
In this study, we have shown that homozygous deletion of
the mitochondrial chaperone TRAP-1 causes global reprogram-
ming of cellular bioenergetics, with compensatory upregulation
of oxidative phosphorylation and glycolysis transcriptomes,
increased mitochondrial accumulation of cytoprotective chaper-
ones Hsp90 and Hsp27, and a dramatic switch to glycolytic
metabolism, in vivo. This is accompanied by reduced inci-
dence of age-associated pathologies, in vivo, including obesity,
dysplasia and tumor formation, decreased cell proliferation, and
low-level ROS production.
The data presented here refute recent and contradictory
claims that TRAP-1 inhibits mitochondrial SDHB-complex II
activity (Sciacovelli et al., 2013), or, conversely, promotes glycol-
ysis (Yoshida et al., 2013). These preliminary suggestionswere at
oddwith a large body of literature, in which pharmacologic or ge-
netic targeting of TRAP-1 inhibited mitochondrial respiration
(Butler et al., 2012; Chae et al., 2013), impaired mitochondrial
quality control (Costa et al., 2013), caused oxidative damage
(Butler et al., 2012; Pridgeon et al., 2007), and suppressed ATP
production (Agorreta et al., 2014; Chae et al., 2012). Consistent
with this model, we found that homozygous deletion of TRAP-1
resulted in decreased SDHB expression, reflecting loss of pro-
tein-folding quality control in mitochondria (Chae et al., 2013).
Mechanistically, this role of TRAP-1 in organelle protein homeo-
stasis (Chae et al., 2013) emerged here as a critical requirement
for mitochondrial bioenergetics. Accordingly, a compensatory
upregulation of virtually every effector of oxidative phosphoryla-
tion and glycolysis in TRAP-1/ mice was sufficient to restore
complex II activity, increase mitochondrial respiration throughCell Reports 8, 671–677, August 7, 2014 ª2014 The Authors 675
higher activity of complex III and IV (Wallace, 2012), and impart a
‘‘pseudo-Warburg’’ glycolytic phenotype validated in whole-
body 18F-FDG PET/CT analysis, in vivo. Together, these findings
reinforce a pivotal role of TRAP-1 in maintaining mitochondrial
homeostasis and bioenergetics (Chae et al., 2013), not sup-
pressing it (Sciacovelli et al., 2013).
At variance with recent claims of TRAP-1 as a ‘‘tumor suppres-
sor’’ (Yoshida et al., 2013), older TRAP-1/ mice were instead
significantly healthier than their age-matched WT littermates,
with significantly reduced obesity, inflammatory and degenera-
tive pathologies, or spontaneous dysplastic lesions, including
tumor formation. More work is required to conclusively dissect
the observed phenotype. However, increased mitochondrial
respiration, as paradoxically induced as compensation for
TRAP-1 loss (this study), has been associatedwith extended life-
span in model organisms (Guarente, 2008), potentially contrib-
uting to the increased longevity afforded by calorie restriction
(Nisoli et al., 2005). In this context, low levels of mitochondrial
respiration-derived ROS, as demonstrated here in TRAP-1/
mice, may activate ‘‘retrograde’’ gene expression mechanisms
of adaptation and cytoprotection (Merksamer et al., 2013) and
exert beneficial effects in aging (Schulz et al., 2007). In addition,
the combination of a chronic DNA damage response, which
opposes malignant transformation (Gorgoulis et al., 2005), and
impaired proliferative capacity, as observed here in TRAP-1/
cells, may further preserve organ integrity during aging.
A pivotal function of TRAP-1 in mitochondrial homeostasis, as
reinforced here, suggests that models of extramitochondrial bio-
energetics, i.e., aerobic glycolysis (Ward and Thompson, 2012)
may not fully recapitulate the complexity of metabolic reprog-
ramming in tumors (Wallace, 2012). In this context, TRAP-1-
directed mitochondrial metabolism may be important to support
highly energy-demanding traits of tumor cells, for instance, cell
invasion (Caino et al., 2013) or cell proliferation (this study), espe-
cially under conditions of chronic nutrient deprivation. In parallel,
ATP produced under these conditions may blunt tumor suppres-
sion mechanisms driven by AMPK activation (Liang and Mills,
2013), escape autophagic cell death (Kimmelman, 2011), and
preserve mTOR signaling (Guertin and Sabatini, 2007), all key
requirements of tumor progression, in vivo. Consistent with this
view, oxidative phosphorylation is being increasingly recognized
as a key requirement of aggressive tumor behavior, preserving
a cancer stem cell phenotype (Janiszewska et al., 2012), and
promoting drug resistant disease (Haq et al., 2013). Together
with its broad cytoprotective functions, these properties make
TRAP-1 a uniquely attractive therapeutic target in cancer, suit-
able to disable multiple pathways of bioenergetics, cell survival,
and adaptation in genetically heterogeneous tumors (Altieri et al.,
2012).
EXPERIMENTAL PROCEDURES
Generation of TRAP-1 Knockout Mice
All procedures involving animals were approved by an Institutional Animal
Care and Use Committee (IACUC) at The Wistar Institute. A murine 129P2
ES clone E150H04, containing an insertional mutation downstream of the
first exon of the TRAP-1 gene (rFlipROSAßgeo vector) was obtained from
the German Gene Trap Consortium. Splinkerette PCR sequence of the ES
clone is available at http://www.ncbi.nlm.nih.gov/nucgss/FI570935.1.676 Cell Reports 8, 671–677, August 7, 2014 ª2014 The AuthorsFollowing pronuclear injections, zygotes were transferred to pseudopregnant
C57BL/6 female mice and resulting chimeric male mice were crossed with
C57BL/6 females to obtain mice heterozygous for the insertional mutation.
The colony was maintained on a mixed B6/129 background by brother 3 sis-
ter mating.
Statistical Analysis
Data were analyzed using the two-sided unpaired t tests using a GraphPad
software package (Prism 4.0) for Windows. The Kolmogorov-Smirnov two-
sample test was used to analyze standardized uptake values (SUVs) in WT
and TRAP-1/ mice in PET/CT experiments using StatXact 9. Data are ex-
pressed as mean ± SD or mean ± SEM of replicates from a representative
experiment out of at least three independent determinations. A p value of
<0.05 was considered as statistically significant.
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